Grant Alerts: Health Research (Week of 4.17 to 4.21)

Below is a recap of research funding opportunities that were recently announced, nationwide. While these alerts are intended to provide you with a broad-reaching overview of the opportunities available, we certainly want to hear if there are specific opportunities that you would like to pursue. Please let your Content Director know if you have any questions or are interested in learning more.

Our Grant Alerts dashboard profiles relevant previously announced national-level funding opportunities, which can be sorted by type, agency/funder, and date. Also, your dedicated Content Director and Relationship Director are ready to help with custom research solutions to the challenges you are facing.

Grant Name:	Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01) (NIH)
Summary:	This program invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography or single photon emission computed tomography imaging in human brain and the incorporation of pilot or clinical feasibility evaluation from previously collected data in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET ligands for use in clinical research.
Eligibility:	There are no eligibility restrictions.
Dates:	Standard NIH dates apply through February 2026.

Grant Name:	Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21) (NIH)
Summary:	This program aims to support tool or technology development projects that will open new areas of science or translational research. The projects supported by this FOA must involve development activities, which could include prototyping of a new tool or significant improvement, adaptation, or optimization of an existing technology. In addition to development activities, projects may also include proof-of-concept studies and refinement of technical specifications for subsequent deployment of the technology in laboratory or clinical settings.
Eligibility:	There are no eligibility restrictions.
Dates:	Standard NIH dates apply through October 2024.

Grant Name:	Understanding Expectancies in Cancer Symptom Management (R01) (NIH)
Summary:	This program aims to support mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. Expectancies are defined in this context as beliefs about future outcomes, including one’s response to cancer or cancer treatment.
Eligibility:	There are no eligibility restrictions.
Dates:	Standard NIH dates apply through February 2026.

Grant Name:	Integration and Analysis of BRAIN Initiative Data (R01) (NIH)
Summary:	This program solicits applications to develop informatics tools for analyzing, visualizing, and integrating data related to the BRAIN Initiative or to enhance our understanding of the brain. The tools supported under this NOFO will make use of relevant data standards and will be built so that they can be integrated into the data repositories, both of which are created in awards under the other NOFOs of the BRAIN initiative informatics program. The tools must be user-friendly in accessing and analyzing data from appropriate data archives, and should analyze/visualize data without requiring users to download data. The tools should also allow data to be combined for analysis/visualization from multiple locations.
Eligibility:	There are no eligibility restrictions.
Dates:	LOIs are due 30 days before standard NIH dates through June 2024.

Grant Name:	Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21) (NIH)
Summary:	This program invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics toward clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.
Eligibility:	There are no eligibility restrictions.
Dates:	LOIs are due 30 days before standard NIH dates through October 2024.

Grant Name:	Centers of Excellence in Genomic Science (RM1) (NIH)
Summary:	This program establishes academic Centers for advanced genome research. Each CEGS award supports a multi-investigator, interdisciplinary team to develop integrated, transformative genomic approaches to address a biomedical problem. A CEGS project will address a critical issue in genomic science, genomic medicine, or computational genomics, proposing a highly innovative solution that would be a major advance. The research will entail substantial risk, balanced by outstanding scientific and management plans and very high potential payoff.
Eligibility:	There are no eligibility restrictions.
Dates:	LOIs are due by May 11, 2023, and May 10, 2024.

Grant Name:	Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33) (NIH)
Summary:	This program uses a R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders, including fundamental circuitry and behavior relevant to substance use.
Eligibility:	There are no eligibility restrictions.
Dates:	LOIs are due 30 days before standard NIH dates through March 2026.

Grant Name:	Maternal Health Research Collaborative for MSI Research Centers (HRSA)
Summary:	This program aims to build the capacity for MSIs to conduct quantitative and/or qualitative maternal health research to fully understand and address the root causes of disparities in maternal mortality, severe maternal morbidity, and maternal health outcomes, and to find community-based solutions to address these disparities and advance health equity.
Eligibility:	Only MSIs may apply.
Dates:	Proposals are due by June 12, 2023.

About Hanover Research: Founded in 2003, Hanover Research is a global research and grant development firm. The Hanover Grants practice provides research development, grant writing, and strategic advising support to a wide range of institutions and organizations. Our professionals deliver customized proposal review, revision, and production support, while also helping to align strategic priorities to funding trends and opportunities at all levels. To learn more about Hanover Research, visit www.hanoverresearch.com.